Health Condition 1: null- Diabetes Mellitus Health Condition 2: E08-E13- Diabetes mellitus
Conditions
Interventions
Intervention1: Biphasic insulin aspart I.P.
(NovoMix� 30 Penfill®): Mixture of insulin aspart and
protamine crystallised insulin aspart, dose-NovoMix 30 50 70, 24 hours-duration, subcutaneous admin
Sponsors
Novo Nordisk India Private Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. The decision to initiate treatment with commercially available BIAsp 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study. 2. Patients selected by their physician for participation in the study, who are likely to be able and willing to pay for the BIAsp 30 treatment for at least 12 weeks from baseline visit as assessed by the treating physician. 3. Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 4. Male or female more than or equal to 18 years at time of informed consent. 5. Diagnosed with T2DM and treated with BHI in vials for at least three consecutive months at time of informed consent.
Exclusion criteria
Exclusion criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Concurrent participation in any other clinical trial or study. 3. Patients previously treated with insulin analogues. 4. Known or suspected hypersensitivity to study product (or any of the excipients of the study product; a full list of excipients is provided in Summary of product characteristics (SmPC) of NovoMix® 3011) or related products. 5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation. 6. Patients who are unable to read or write (illiterate).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to assess the proportion of patients with T2DM, previously treated with BHI in vials for at least 3 months, who are able and willing to pay for BIAsp 30 in a FlexPen® at Week 12 following the first prescription of BIAsp 30 (as part of a patientâ??s usual care).Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess patientsâ?? preferences for BIAsp 30 attributes and satisfaction with treatment in general and the delivery device in particular. To investigate any difference in the characteristics of patients with T2DM that were treated with BHI in vials prior to the first prescription of BIAsp 30 and who are willing to pay for BIAsp 30 in a pen device after 12 weeks of treatment versus patients who are not able or willing to pay.Timepoint: 6 months | — |
Countries
Egypt, India
Contacts
Public ContactDr Bharathi R
Novo Nordisk India Private Ltd.
Outcome results
None listed